Document is current
Any future updates will be listed below
-
Authors
Luu, Maik
Riester, Zeno https://orcid.org/0000-0002-1032-5429
Baldrich, Adrian
Reichardt, Nicole
Yuille, Samantha
Busetti, Alessandro
Klein, Matthias
Wempe, Anne
Leister, Hanna
Raifer, Hartmann
Picard, Felix
Muhammad, Khalid https://orcid.org/0000-0001-6488-1722
Ohl, Kim https://orcid.org/0000-0002-3750-9527
Romero, Rossana
Fischer, Florence
Bauer, Christian A.
Huber, Magdalena https://orcid.org/0000-0002-2963-0693
Gress, Thomas M.
Lauth, Matthias
Danhof, Sophia https://orcid.org/0000-0003-1316-0241
Bopp, Tobias https://orcid.org/0000-0002-3232-8065
Nerreter, Thomas https://orcid.org/0000-0002-0493-1369
Mulder, Imke E.
Steinhoff, Ulrich
Hudecek, Michael https://orcid.org/0000-0002-2280-2202
Visekruna, Alexander https://orcid.org/0000-0002-5207-9545
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG-KFO325)
- License Information
-
More Information
Article History
Received: 6 April 2020
Accepted: 8 June 2021
First Online: 1 July 2021
Competing interests
: M.L., M. Hudecek, and A.V. are inventors on a patent application related to the use of pentanoate that has been filed by Philipps-University Marburg and Julius-Maximilians University Würzburg (WO2021/058811A1). The title of the patent application is the following one: “Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy”. All other authors have no competing interests.
